Novel T-Cell Immunotherapies Market: Focus on ?d T-Cells, Tregs, Activated T-Cells, Virus-driven T-Cells and T-Cell Vaccines - Distribution by Type of T-cell Therapy (Activated T-cell, T-cell Vaccine, Treg and Virus-driven T-cell), Target Indications (Br

Novel T-Cell Immunotherapies Market: Focus on γδ T-Cells, Tregs, Activated T-Cells, Virus-driven T-Cells and T-Cell Vaccines - Distribution by Type of T-cell Therapy (Activated T-cell, T-cell Vaccine, Treg and Virus-driven T-cell), Target Indications (Brain Tumor, Pancreatic Cancer, Breast Cancer, Lung Cancer, Nasopharyngeal Cancer, Multiple Myeloma, Hepatocellular Carcinoma, Post-transplant Infection, Diabetes and Others), Key Players and Key Geographies (North America, Europe, Asia Pacific and Rest of the World): Global Forecast, 2021-2030

In recent years, adoptive T-cell therapy (ACT) has emerged as a potent and viable type of therapeutic intervention, which is applicable to a variety of oncological and non-oncological indications. Owing to its obvious benefits, which include high target specificity, customization potential and the ability to generate immunological memory, this form of therapy has garnered significant attention among drug developers, investors and consumers, alike. In fact, several of the initial variants of T-cell based pharmacological interventions, namely those based on chimeric antigen receptors (CARs), and antigen sensitized T-cell receptors (TCRs), are already approved and available in the market. Lately, several novel types of T-cell therapies, such as γδ T-cells, Tregs, activated T-cells, virus-driven T-cells and T-cell vaccines, have demonstrated therapeutic proof-of-concept and shown promise in the early stages of clinical research, as well. Much like their predecessors, these experimental treatment paradigms are also capable of selectively eradicating diseased cells from the body and are characterized by favorable side effect profiles. At present, the novel T-cell immunotherapies pipeline features over 200 product candidates and is anticipated to grow in the foreseen future. Further, more than 35 such therapies, including Tab-cel® (Atara Biotherapeutics), CLBS03 (Caladrius Biosciences), TVI-Brain-1 (TVAX Biomedical), Viralym-M (AlloVir) and ALS001 (Coya Therapeutics), are already being evaluated in the advanced stages of development.
So far, more than 105 academic / research institutes, as well as over 50 industry players, across the world, have made notable contributions to this upcoming segment of the T-cell immunotherapies market. Moreover, multiple collaborations have been inked between both industry and non-industry players in order to advance the development of various pipeline candidates, over the past decade alone. It is also worth highlighting that, in the last five years, capital investments worth over USD 4 billion were made by VC firms / other strategic investors with interest in the healthcare domain. Driven by promising clinical trial data and lucrative funding, this niche, but emerging market, is poised to witness healthy growth over the next decade.

SCOPE OF THE REPORT
The “Novel T-Cell Immunotherapies Market: Focus on γδ T-Cells, Tregs, Activated T-Cells, Virus-driven T-Cells and T-Cell Vaccines - Distribution by Type of T-cell Therapy (Activated T-cell, T-cell Vaccine, Treg and Virus-driven T-cell), Target Indications (Brain Tumor, Pancreatic Cancer, Breast Cancer, Lung Cancer, Nasopharyngeal Cancer, Multiple Myeloma, Hepatocellular Carcinoma, Post-transplant Infection, Diabetes and Others), Key Players and Key Geographies (North America, Europe, Asia Pacific and Rest of the World), Industry Trends and Global Forecast, 2021-2030” report features an extensive study of the current market landscape and the associated future potential. The report highlights efforts of both industry players and academic organizations. Amongst other elements, the report features the following:
 A detailed assessment of the current market landscape of novel T-cell immunotherapies, with respect to type of T-cell therapy (activated T-cells, virus driven T-cells, Tregs, γδ T-cells, T-cell vaccines and NK T-cells), phase of development (preclinical, phase I, phase I/II, phase II, phase III and marketed), therapeutic area (oncological disorders, infectious diseases, post-transplant infections, autoimmune disorders, metabolic disorders and neurological disorders), popular target indication (lung cancer, breast cancer, cytomegalovirus infection, glioblastoma, hepatocellular carcinoma, acute myeloid leukemia, ovarian cancer, type 1 diabetes mellitus, sarcoma, HIV infections and pancreatic cancer), source of T-cell (autologous and allogeneic), route of administration (intravenous, intratumoral, subcutaneous, inhalation and intramuscular), dose frequency (multiple dose, single dose and split dose), target patient segment (children, adults and seniors), type of therapy (monotherapy and combination therapy) and type of developer (industry and non-industry). In addition, the chapter includes details related to novel T-cell immunotherapies developers, along with information on their respective year of establishment, company size, location of headquarters and most active players (in terms of number of pipeline candidates).
 An in-depth analysis of completed, ongoing and planned clinical studies of various novel T-cell immunotherapies, based on various relevant parameters, such as trial registration year, trial phase, trial recruitment status, study design, type of sponsor / collaborator, leading industry players (in terms of number of registered trials conducted), enrolled patient population and key geographical regions.
 An analysis of the partnerships that have been established in this domain during the period 2015-2021 (till March), covering R&D agreements, product development agreements, product licensing agreements, acquisitions, service agreements, manufacturing agreements and other related agreements.
 An analysis of investments that have been made into companies which have proprietary novel T-cell based products / technologies, during period 2014 and 2021 (till March). The various type of funding instances reported in this domain include seed financing, venture capital financing, capital raised from IPOs and subsequent public offerings, grants and debt financing.
 Detailed profiles of clinical stage, novel T-cell therapies (phase I/II or above); each profile features an overview of the therapy, current development status, key clinical trial results, dosage regimen, details related to its manufacturing and recent developments.
 A case study on manufacturing of cell therapy products, highlighting the key challenges associated with the production of such therapies. In addition, it features a detailed list of contract service providers and in-house manufacturers involved in this market.
 Elaborate profiles of prominent players engaged in the development of novel T-cell immunotherapies. Each profile features a brief overview of the company, details related to its financials (if available), product portfolio, recent developments and manufacturing capability.
 A case study on regulatory T-cells, highlighting the mechanism of Tregs, key challenges associated with the production of such therapies and recent developments in the Tregs market.

One of the key objectives of the report was to estimate the existing market size and identify potential growth opportunities for novel T-cell immunotherapies over the coming decade. The report also includes likely sales forecasts of novel T-cell immunotherapies that are in the mid to late stages of development. Additionally, it features market size projections for the overall novel T-cell immunotherapies market, wherein both the current and upcoming opportunity is segmented across [A] type of T-cell therapy (activated T-cell, T-cell vaccine, Treg and virus-driven T-cell), [B] target indication (brain tumour, pancreatic cancer, breast cancer, lung cancer, nasopharyngeal cancer, multiple myeloma, hepatocellular carcinoma, post-transplant infection, diabetes and others), [C] key players and [D] key geographies (North America, Europe, Asia Pacific and rest of the world). In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely the conservative, base and optimistic scenarios, which represent different tracks of the industry’s evolution.

The opinions and insights presented in this study were influenced by discussions conducted with multiple stakeholders in this domain. The report features detailed transcripts of interviews held with the following individuals:
 Peter Hoang (Chief Executive Officer, Marker Therapeutics)
 Patrick Dougherty (Senior Vice President, Strategy, Planning and Operations, WindMIL Therapeutics)

RESEARCH METHODOLOGY
The data presented in this report has been gathered via secondary and primary research. For all our projects, we conduct interviews / surveys with experts in the area (academia, industry and other associations) to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market will evolve across different regions and segments. Where possible, the available data has been checked for accuracy from multiple sources of information.

The secondary sources of information include:
 Annual reports
 Investor presentations
 SEC filings
 Industry databases
 News releases from company websites
 Government policy documents
 Industry analysts’ views

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

KEY QUESTIONS ANSWERED
 What are the prevalent R&D trends related to novel T-cell immunotherapies?
 What are the key therapeutic areas for which novel T-cell immunotherapies have been / are being developed?
 What are the key challenges faced by stakeholders engaged in this domain?
 Who are the leading industry and non-industry players in this market?
 Which players have made significant investments in this domain?
 What type of partnership models are commonly adopted by industry stakeholders?
 What are the factors that are likely to influence the evolution of this upcoming market?
 How is the current and future market opportunity likely to be distributed across key market segments?

CHAPTER OUTLINES
Chapter 2 provides an executive summary of the insights captured during our research. It offers a high-level view on the likely evolution of the novel T-cell immunotherapy market in the short to mid-term and long term.

Chapter 3 provides a general overview of novel T-cell immunotherapies, including activated T-cell, virus driven T-cells, Tregs, γδ T-cells, T-cell vaccine and NK T-cells. It also includes information on the key considerations for developing T-cell immunotherapies.

Chapter 4 includes detailed assessment on close to 205 novel T-cell immunotherapy candidates that are currently approved or are in different stages of development. It features a comprehensive analysis of pipeline molecules with respect to type of T-cell therapy (activated T-cells, virus driven T-cells, Tregs, γδ T-cells, T-cell vaccines and NK T-cells), phase of development (preclinical, phase I, phase I/II, phase II, phase III and marketed), therapeutic area (oncological disorders, infectious diseases, post-transplant infections, autoimmune disorders, metabolic disorders and neurological disorders), popular target indication (lung cancer, breast cancer, cytomegalovirus infection, glioblastoma, hepatocellular carcinoma, acute myeloid leukemia, ovarian cancer, type 1 diabetes mellitus, sarcoma, HIV infections and pancreatic cancer), source of T-cell (autologous and allogeneic), route of administration (intravenous, intratumoral, subcutaneous, inhalation and intramuscular), dose frequency (multiple dose, single dose and split dose), target patient segment (children, adults and seniors), type of therapy (monotherapy and combination therapy) and type of developer (industry and non-industry. In addition, the chapter includes details related to novel T-cell immunotherapies developers, along with information on their respective year of establishment, company size, location of headquarters and most active players (in terms of number of pipeline candidates).

Chapter 5 provides detailed profiles of clinical stage, novel T-cell therapies being evaluated in clinical stages (phase I/II or above); each profile features an overview of the therapy, current development status, key clinical trial results, dosage regimen, details related to its manufacturing information and recent developments.

Chapter 6 presents an in-depth analysis of completed, ongoing, and planned clinical studies of various novel T-cell immunotherapies, based on various relevant parameters, such as trial registration year, trial phase, trial recruitment status, study design, type of sponsor / collaborator, leading industry players (in terms of number of registered trials conducted), enrolled patient population and key geographical regions.

Chapter 7 features an elaborate discussion and analysis of the various collaborations and partnerships that have been inked amongst players in this market, during the period 2015-2021 (till March). Further, the partnership activity in this domain has been analyzed based on various parameters, such as year of partnership, type of partnership model (R&D agreements, product development agreements, product licensing agreements, acquisitions, service agreements, manufacturing agreements and others), type of T-cell, target therapeutic area and regional distribution of the collaborations.

Chapter 8 provides details on the various investments and grants that have been awarded to players focused on the development of novel T-cell immunotherapies. It includes a detailed analysis of the funding instances that have taken place during the period 2014 to 2021 (till March), highlighting the growing interest of venture capital (VC) community and other strategic investors in this domain.

Chapter 9 provides insights on cell therapy manufacturing, highlighting the current challenges that exist in this domain, and the pre-requisites for owning and maintaining cell therapy manufacturing sites. It includes a detailed list of various cell therapy manufacturers, covering both contract manufacturing organizations and companies with in-house manufacturing capabilities. For the players mentioned in the chapter, we have included details on location of various manufacturing facilities, the products being manufactured, scale of operation and compliance to cGMP standards.

Chapter 10 includes brief profiles of prominent players engaged in the development of novel T-cell immunotherapies. Each profile features a brief overview of the company, details related to its financials (if available), product portfolio, recent developments and manufacturing capability.

Chapter 11 provides insights on regulatory T-cells, highlighting the mechanism of Tregs, key challenges associated with the production of such therapies and recent developments in the Tregs market.

Chapter 12 features an elaborate discussion on the future commercial opportunity offered by novel T-cell immunotherapies. It provides a comprehensive market forecast analysis for molecules that are approved or are in phase I/II and above development stages taking into consideration the target patient population, existing / future competition, likely adoption rates and the likely price of different therapies. The chapter also presents a detailed market segmentation on the basis of [A] type of T-cell therapy (activated T-cell, T-cell vaccine, Treg and virus-driven T-cell), [B] target indication (brain tumour, pancreatic cancer, breast cancer, lung cancer, nasopharyngeal cancer, multiple myeloma, hepatocellular carcinoma, post-transplant infection, diabetes and others), [C] key players and [D] key geographies (North America, Europe, Asia Pacific and rest of the world).

Chapter 13 summarizes the overall report. In this chapter, we have provided a list of key takeaways from the report, and expressed our independent opinion related to the research and analysis described in the previous chapters.

Chapter 14 provides the transcripts of interviews conducted with key stakeholders of this market. In this chapter, we have presented the details of our conversation with Peter Hoang (Chief Executive Officer, Marker Therapeutics) and Patrick Dougherty (Senior Vice President, Strategy, Planning and Operations, WindMIL Therapeutics).

Chapter 15 is an appendix, which provides tabulated data and numbers for all the figures provided in the report.

Chapter 16 is an appendix, which contains the list of companies and organizations mentioned in the report.

LIST OF COMPANIES AND ORGANIZATIONS

The following companies and organizations have been mentioned in the report.
1. 8VC
2. Abingworth
3. Acer Therapeutics
4. Acorn Pacific Ventures
5. Adaptate Biotherapeutics
6. Agency for Science, Technology and Research (A*STAR)
7. AgenTus Therapeutics
8. Agenus
9. Alexandria Venture Investments
10. Allele Capital Partners
11. AlloVir
12. Andalusian Public Foundation for Health Research Management of Seville (FISEVI)
13. Anhui Kedgene Biotechnology
14. Anhui Provincial Hospital
15. ARCH Venture Partners
16. ArrowMark Partners
17. ARSEP Foundation
18. Assistance Publique – Hôpitaux de Paris (AP-HP)
19. Atara Biotherapeutics
20. Austin Health
21. Autoimmunity Centers of Excellence
22. Barer & Son Capital
23. Bayer
24. Baylor College of Medicine
25. BB Pureos Bioventures
26. Beijing 302 Hospital
27. Beijing Cancer Hospital
28. Beijing Doing Biomedical Technology
29. Beijing GD Initiative Cell Therapy Technology
30. Beijing Genomics Institute
31. Beijing Mabworks Biotech
32. Beijing Tongren Hospital
33. Beijing Youan Hospital
34. Bellicum Pharmaceuticals
35. Benaroya Research Institute at Virginia Mason (BRI)
36. Besançon University Hospital
37. Beth Israel Deaconess Medical Center
38. Betta Pharmaceuticals
39. BHT Lifescience Australia
40. Bill and Melinda Gates Foundation
41. BioCentriq
42. Bios Partners
43. Biox Biosciences
44. Blood and Tissue Bank
45. Bloom Burton
46. bluebird bio
47. Bpifrance
48. Brigham and Women's Hospital
49. Bristol Myers Squibb
50. British Society for Haematology
51. Bordeaux University Hospital Center (CHU)
52. Boston Children's Hospital
53. Cairo University
54. Caladrius Biosciences
55. California Institute for Regenerative Medicine (CIRM)
56. Cambridge University Hospitals NHS Foundation Trust
57. Cancer Prevention Research Institute of Texas
58. Cancer Research Institute
59. Cancer Research Technology
60. Case Western Reserve University
61. Celldex Therapeutics
62. Cell Medica
63. Celgene
64. Cellenkos
65. Center for Cell and Gene Therapy
66. Center for Clinical and Translational Sciences (CCTS)
67. Centre for Commercialisation of Cancer Immunotherapy (C3i)
68. Central Hospital, Nancy, France
69. Central South University
70. Charite – Universitatsmedizin Berlin
71. Changi General Hospital (CGH)
72. Chengdu MedGenCell
73. Children's Hospital Los Angeles
74. Children's Hospital of Philadelphia
75. Children's National Research Institute (CNRI)
76. Children's Oncology Group
77. Children's Research Institute
78. Chinese Academy of Medical Sciences
79. Chinese PLA General Hospital (CPGH)
80. Cincinnati Children's Hospital Medical Center
81. City of Hope
82. Clinical Research Malaysia (CRM)
83. Cognate BioServices
84. Columbia University
85. Coya Therapeutics
86. CRISPR Therapeutics
87. Cryoport
88. CytoMed Therapeutics
89. Dana-Farber Cancer Institute
90. DCVC Management
91. Department of Health Valencia La Fe
92. Diabetes Research Institute Foundation Canada (DRIFCan)
93. DS Asset Management
94. Duke-NUS Medical School
95. Duke University
96. Dutch Cancer Society
97. EcoR1 Capital
98. EDBI
99. Emerson Collective
100. Emmes
101. Erciyes University
102. Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
103. Euchloe Bio (acquired by Tessa Therapeutics)
104. Eureka Therapeutics
105. European Commission
106. Eutilex
107. F2 Ventures
108. Faculty of Medicine, University of Indonesia (FKUI)
109. Fate Therapeutics
110. Ferring Pharmaceuticals
111. Fidelity Management and Research
112. Fondazione IRCCS Policlinico San Matteo
113. Fred Hutchinson Cancer Research Center
114. Friedrich-Alexander University Erlangan-Nuremberg (FAU)
115. French Blood Establishment (EFS)
116. Friedreich’s Ataxia Research Alliance (FARA)
117. Fuda Cancer Hospital
118. GammaCell Bio-Technologies
119. GammaDelta Therapeutics
120. GC Pharma
121. GentiBio
122. Ghent University Hospital
123. Gilde Healthcare
124. Gilead Sciences
125. GlaxoSmithKline
126. G.N. Tech Venture
127. GP Capital
128. Guangdong Xiangxue Precision Medical Technology
129. Guangzhou Anjie Biomedical Technology
130. Guy's and St Thomas' NHS Foundation Trust
131. Hackensack Meridian Health
132. Hangzhou Cancer Hospital
133. Hannover Medical School
134. Harbin Medical University
135. Harris Health System (formerly known as the Harris County Hospital District)
136. Heidelberg University Hospital
137. Heliconia Capital Management
138. HengRui YuanZheng Bio-Technology
139. Heritas Capital
140. H. Lee Moffitt Cancer Center and Research Institute
141. HMP Partners
142. Hoxworth Blood Center
143. Hunan Zhaotai Yongren Medical Innovation
144. Icahn School of Medicine at Mount Sinai
145. ILTOO Pharma
146. Immune Tolerance Network
147. Immunocore
148. Imperial College London
149. InnoCare Pharma
150. International Multidisciplinary Research Foundation (IMRF)
151. IN8bio
152. Incyte
153. Innovate UK
154. Inserm
155. Institute of Hematology and Blood Diseases Hospital
156. Instituto de Investigación Sanitaria Valdecilla (IDIVAL)
157. Intrexon
158. IRCCS Company Hospital- University of Bologna
159. ITOCHU
160. Janssen Biotech
161. JDRF T1D Fund
162. Jinan University
163. Johns Hopkins University
164. Jonsson Comprehensive Cancer Center
165. Juvenile Diabetes Research Foundation (JDRF)
166. Kaiser Permanente
167. Karst Peak Capital
168. King’s College London
169. KK Women's and Children's Hospital
170. Knight Therapeutics
171. Kolon Investment
172. Kuur Therapeutics
173. Kyverna Therapeutics
174. LAVA Therapeutics
175. Leukemia and Lymphoma Society
176. Liana's Dream Foundation
177. Lifeforce Capital
178. Lightspeed Venture Partners
179. Lilly Asia Ventures
180. Lonza
181. Ludwig Institute for Cancer Research
182. Lupus Ventures
183. Lyell Immunopharma
184. Lymphact (acquired by GammaDelta Therapeutics)
185. Mahidol University
186. Maisonneuve-Rosemont Hospital
187. Massachusetts General Hospital
188. Matrix Capital Management
189. Mayo Clinic
190. MD Anderson Cancer Center
191. Medical College of Wisconsin
192. Medical Research Council
193. Medical University of Lublin
194. Medical University of Vienna
195. Memorial Sloan Kettering Cancer Center
196. Merck Sharp & Dohme
197. Methodist Hospitals
198. MIGAL Galilee Research Institute
199. Miltenyi Biomedicine
200. Miltenyi Biotec
201. Ministry of Science and Higher Education, Poland
202. MMH Institute for Transfusion Medicine
203. Mogrify
204. Mount Sinai Hospital
205. MPM Capital
206. MRL Ventures Fund
207. Mubadala Investment Company
208. Multiple Myeloma Research Foundation (MMRF)
209. Nanjing Drum Tower Hospital (Nanjing Gulou Yi Yuan)
210. Nanjing Medical University
211. Nantes University Hospital
212. National Cancer Institute
213. National Center for Tumor Diseases (NCT)
214. National Health and Medical Research Council (NHMRC)
215. National Heart, Lung, and Blood Institute (NHLBI)
216. National Institute for Health Research (NIHR)
217. National Institute of Allergy and Infectious Diseases (NIAID)
218. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
219. National Institutes of Health (NIH)
220. National Marrow Donor Program
221. National University Hospital (NUH)
222. Nationwide Children's Hospital
223. ND Capital
224. Nice University Hospital
225. Neon Therapeutics
226. New Enterprise Associates
227. New York Medical College
228. NexImmune
229. Northpond Ventures
230. Northwestern University
231. Nova Immunotherapeutics
232. Novartis Venture Fund
233. Novo Ventures
234. NYU Langone Health
235. Oceanpine Capital
236. Octagon Capital
237. Ohio University
238. Oncovir
239. Opexa Therapeutics
240. OrbiMed
241. Orca Bio
242. Ospedale San Raffaele
243. OU Health Stephenson Cancer Center
244. PapiVax Biotech
245. Pancreatic Cancer Action Network
246. University Paris-Est Creteil Val de Marne (formerly known as the Université Paris XII)
247. Parker Institute for Cancer Immunotherapy
248. Peking University People's Hospital
249. Penn State Health Milton S. Hershey Medical Center
250. Peter MacCallum Cancer Institute
251. PersonGen BioTherapeutics (Suzhou)
252. Pfizer
253. Piedmont Capital Partners
254. Pierce Phillips Charity
255. Pierre and Marie Curie University (UPMC)
256. Prometheus Laboratories
257. Providence Cancer Institute
258. Qiming Venture Partners
259. QIMR Berghofer Medical Research Institute
260. Quell Therapeutics
261. Queensland Institute of Medical Research (QIMR) Berghofer
262. RA Capital Management
263. Radboud University
264. Redmile Group
265. Rho Federal Systems Division
266. Roswell Park Cancer Institute
267. Samsara BioCapital
268. Sanford Health
269. Sangamo Therapeutics
270. Sanofi Ventures
271. Seattle Children’s Research Institute
272. Second Xiangya Hospital of Central South University
273. Sengkang General Hospital
274. Seoul National University Hospital (SNUH)
275. Shanghai General Hospital
276. Shanghai Houchao Biotechnology
277. Shanghai iCELL Biotechnology
278. Shanghai Jiao Tong University School of Medicine
279. Shanghai Public Health Clinical Center
280. Sheffield Institute for Translational Neuroscience
281. Shenzhen Geno-Immune Medical Institute
282. Shenzhen Hornetcorn Biotechnology
283. Shenzhen Second People's Hospital
284. Shenzhen Third People's Hospital
285. Sichuan University
286. Singapore General Hospital
287. Siriraj Hospital
288. Sixth Affiliated Hospital
289. SNU Bio Angel
290. SoftBank Vision Fund
291. Solving Kids' Cancer
292. Sonoma Biotherapeutics
293. Specialized Medical Services-oncology
294. SR One
295. St. George's Hospital
296. St. Jude Children’s Research Hospital
297. Stanford University
298. Sun Yat-sen University
299. Surveyor Capital
300. Syncona
301. SYZ Cell Therapy
302. Takeda Pharmaceutical
303. Targazyme
304. Temasek
305. Tessa Therapeutics
306. Tevogen Bio
307. The Atlantic Philanthropies
308. The Egyptian IVF-ET Center
309. The First Affiliated Hospital of Xi'an Jiaotong University
310. The First Affiliated Hospital of Guangdong Pharmaceutical University
311. The First Affiliated Hospital of Guangzhou Medical University
312. The First Affiliated Hospital of Soochow University
313. The Francis Crick Institute
314. The First People's Hospital of Lianyungang
315. The Invus Group
316. The University of Alabama at Birmingham
317. The University of Kansas Medical Center
318. The University of Utah
319. The V Foundation for Cancer Research
320. Tianjin Medical University Cancer Institute and Hospital
321. TRACT Therapeutics
322. Triumvira Immunologics
323. TVAX Biomedical
324. TxCell
325. UBS Oncology Impact Fund
326. UCL Technology Fund
327. University College London (UCL)
328. University Health Network, Toronto
329. University Hospital Cologne
330. University Hospital of Saint-Étienne
331. University Hospital of Montpellier
332. University Hospital of Würzburg
333. University Hospital Regensburg
334. University of Alabama
335. University of Alberta
336. University of Arkansas
337. University of California
338. University of Cambridge
339. University of Cincinnati
340. University of Colorado
341. University of Kansas Medical Center
342. University of Kentucky
343. University of Liege
344. University of Maryland
345. University of Miami
346. University of Michigan
347. University of Minnesota Medical Center
348. University of Pennsylvania
349. University of Perugia
350. University of Pittsburgh
351. University of Regensburg
352. University of Sydney
353. University of Technology Sydney
354. University of Texas
355. University of Wisconsin
356. University of Wisconsin Carbone Cancer Center (UWCCC)
357. University of Wisconsin School of Medicine and Public Health
358. UW Health
359. Vall d'Hebron Institute of Oncology
360. V Foundation for Cancer Research
361. Versant Ventures
362. Vertex Ventures
363. Veterans Affairs (VA) Office of Research and Development
364. Vida Ventures
365. ViGenCell
366. Vineti
367. Vir Biotechnology
368. Viva Biotech
369. VT BIO
370. Vyriad
371. Washington University School of Medicine
372. Wellcome Trust
373. Westlake Village BioPartners
374. WindMIL Therapeutics
375. Wuhan Union Hospital
376. Xiangxue Life Science Research Center
377. Xiangxue Pharmaceutical
378. Yale University
379. Ysios Capital
380. Zhejiang Huahai Pharmaceutical
381. Zhujiang Hospital of Southern Medical University

Please note that the publisher limits purchases by consulting clients to either Consulting Company Team License or Global Site License for Entire Company. Any other selections will not be fulfilled by this publisher.